EP1572256A2 - Procede de production de matieres spongieuses - Google Patents

Procede de production de matieres spongieuses

Info

Publication number
EP1572256A2
EP1572256A2 EP03813570A EP03813570A EP1572256A2 EP 1572256 A2 EP1572256 A2 EP 1572256A2 EP 03813570 A EP03813570 A EP 03813570A EP 03813570 A EP03813570 A EP 03813570A EP 1572256 A2 EP1572256 A2 EP 1572256A2
Authority
EP
European Patent Office
Prior art keywords
sponge
added
material according
production
polymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03813570A
Other languages
German (de)
English (en)
Inventor
Günther Beisel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2002159505 external-priority patent/DE10259505A1/de
Priority claimed from DE20219660U external-priority patent/DE20219660U1/de
Application filed by Individual filed Critical Individual
Publication of EP1572256A2 publication Critical patent/EP1572256A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges

Definitions

  • the present invention relates to a method for producing sponge-like materials and to the sponge-like material produced by the method as such.
  • agents for oral administration which contain polysaccharides containing uronic acid which are stably crosslinked with one another in the form of a sponge-like structure which is poorly soluble or poorly absorbable in water and / or gastrointestinal liquids. These agents are produced in which the polyuron-containing polysaccharides are crosslinked via ionic compounds, frozen, freeze-dried, stably crosslinked via covalent bonds and then dried and, if necessary, pressed.
  • Freeze drying is a time and energy consuming process. For example, frozen collagen plates dry in a high vacuum for about 3 days. This shows that there are high costs for the purchase and maintenance of appropriate freeze drying systems.
  • the object of the present invention is therefore to provide a method for producing sponge-like materials which no longer has the disadvantages described. In particular, time and costs are to be minimized.
  • This object is achieved by a process for the production of sponge-like materials, in which a solution containing polymers is prepared, the solution is frozen, the water is removed by adding suitable substances and finally dried. With this Processes usually result in dried plate-shaped materials. These can be compressed, cut and, if necessary, finally used for other purposes.
  • natural, semi-synthetic or synthetic polymers can be used.
  • suitable synthetic polymers are polyurethanes, polyacrylates, polyesters (e.g. polymeric acid, polyglycolic acid), poly (meth) acrylic acid esters, homo- and copolymers of vinyl acetate.
  • Natural and semi-synthetic polymers include Cellulose, cellulose ether, diethyl cellulose or cellulose esters, such as cellulose diacetate, cellulose triacetate, cellulose acetate propionate,
  • Cellulose acetate and cellulose butyrate e.g. Cellulose derivatives, especially corresponding ethers, e.g. Methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, or sodium carboxymethyl cellulose (preferably those compounds with higher viscosity); natural (anionic) mucilages, e.g. Xanthan gum, guar gum, tragacanth or alginic acid and salts thereof, and the like.
  • insoluble polysaccharides such as chitin or chitin derivatives or microcrystalline cellulose, is also conceivable.
  • Linear or branched chain high molecular weight polymers are particularly preferred according to the invention.
  • examples of such substances are the ski protein, such as keratins, conchagens, fibroins, elastins and collagen.
  • Polysaccharides e.g. Pectins, gelatin.
  • Stably crosslinked polymers are also suitable.
  • uronic acid-containing polysaccharides or their salts are conceivable, which are crosslinked by ionic bonds and are stably crosslinked by additional covalent bonds, for example ester bonds catalyzed by mineral-containing acids.
  • the uronic acid-containing polysaccharides are cross-linked by ionic bonds and additionally cross-linked stably by covalent bonds.
  • Particularly preferred polyuronic acid-containing polysaccharides are alginic acids and their salts (alginates).
  • alginates alginates
  • low-esterified pectins, xanthan, tragacanth, chondroitin sulfate and all other compounds containing uronic acid can also be used according to the invention.
  • Alginic acid is a linear polyuronic acid consisting of alternating proportions of D-mannuronic acid and L-guluronic acid, which are linked together by ⁇ -glycosidic bonds, the carboxyl groups not being esterified.
  • One molecule of alginic acid can be composed of about 150-1050 uronic acid units, with the average molecular weight varying in a range of 30-200 kDa.
  • the polysaccharide alginic acid is a component of the cell walls of brown algae.
  • the proportion of alginic acid in the dry mass of algae can make up to 40%.
  • the alginic acid is obtained by alkaline extraction using methods known per se according to the prior art.
  • the resulting powdered alginic acid is therefore purely vegetable and has a high level of biocompatibility. It can absorb 300 times its own weight in water, forming highly viscous solutions.
  • alginic acid forms so-called gels.
  • the formation of alginate gels in the presence of divalent cations, such as calcium or barium, is described in Shapiro I., et al. (Biomaterials, 1997, 18: 583-90).
  • calcium gluconate also provides suitable divalent cations.
  • all physiologically acceptable poly cations, especially divalent cations can be used.
  • the linear, accordion-like alginate chains are fixed by the free binding sites of the cations, preferably calcium ions, via ionic bonds. This creates a three-dimensional network in which the divalent cations, as in the Smidsrod, et al. (Trends in Biotechnology, 1990, 8:71) shown "egg box model", such as "eggs in an egg carton".
  • Crosslinked polymers made from saccharide acrylates or poly (2-hydroxyethyl methacrylate) gelatin and collagen or chitosan are also known by way of example
  • solutions of the polymers described are prepared.
  • the solutions prepared in this way can be frozen.
  • freezing can also be done with liquid nitrogen. It is preferably frozen at temperatures between -5 and -60 degrees. Temperatures of -10 to -20 degrees are preferred. Temperatures of approximately -20 degrees Celsius are most preferred.
  • freezing takes place over several hours.
  • the length of time depends on the freezing temperature and the temperature of the solution used.
  • the solutions are preferably prepared in such a way that flat plates are formed. Thicknesses between 1 and 10 cm are preferred. 2 to 7 cm are particularly preferred. 3 to 5 cm are most preferred.
  • an agent for strengthening the structure can be added to the polymer solutions.
  • Fibers are particularly suitable for this.
  • Substances with particle sizes between 30 and 800 ⁇ m are preferably used.
  • Particle sizes of 50 to 250 are particularly preferred, very particularly preferably between 80 and 160.
  • inorganic salts can also be added in order to achieve solidification of the gel structure by salt formation.
  • the inorganic salts used are preferably those which are formed from divalent to trivalent metal ions.
  • the metals of the first, second and third main groups of the periodic table are preferably used.
  • Calcium, aluminum, magnesium are preferred according to the invention.
  • Iron salts can also be used.
  • Aluminum and calcium salts are particularly preferred according to the invention. Mixtures of the salt types mentioned in any form, composition and concentration are also suitable.
  • the salts are preferably chlorides, sulfates, gluconates, citrates, acetates.
  • the polymer solutions described are brought into contact with compounds which withdraw the liquid present in them.
  • water is removed from the polymer solutions by adding suitable compounds. The water can be withdrawn from the liquid phase.
  • the polymer solutions are frozen and then the water is removed.
  • the water in particular the water, alcohols, ketones, aqueous solutions of salts, sugars or sugar alcohols are preferably used according to the invention.
  • methanol, ethanol, propanol can preferably be used as alcohols.
  • Isopropyl alcohol is particularly preferred according to the invention.
  • the ketones which can be used according to the invention include methyl and ethyl ketones. Acetones are also preferred according to the invention.
  • ethers can also be used according to the invention.
  • the inorganic metal salts already mentioned are preferred as salt solutions. That is, according to the invention, mono- to trivalent metal ions are particularly suitable.
  • the metals of the first and second main groups of the periodic table are particularly preferred.
  • Particularly preferred salts are chlorides, sulfates, carbonates, acetates.
  • Chlorides of the metals of the first main group of the periodic table are particularly preferred according to the invention.
  • the use of sodium chloride or potassium chloride is very particularly preferred.
  • the person skilled in the art can find out the length of the exposure time of the compounds described for water removal by simple experimentation. As soon as sufficient water has been removed, the liquid is removed by dripping, centrifuging or squeezing. It is then dried.
  • the dried plates can then be compressed, cut and sent for further processing.
  • the sponges produced according to the invention are suitable for a wide variety of applications.
  • the sponges can thus be used as such to produce agents for producing a saturation effect.
  • the foam-like or foam-like material must be able to be easily compressed when it passes through the esophagus. In particular, there must be no discomfort when passing through the esophagus.
  • the material and the type of foam formation it is also essential that it remains swellable without the cell webs being destroyed. After passing through the esophagus, the spongy structure should expand. If necessary, the material can also swell to a size that goes beyond the original volumes.
  • the sponge-like structure can be compressed and decompressed Condition have any shape and size. However, cuboid or rectangular or round configurations are preferred.
  • the material is preferably designed such that the sponge-like structure can be compressed to 1/2 to 1/100, preferably 1/3 to 1/50, particularly preferably 1/5 to 1/20 of its volume or size.
  • the compressed material should preferably be able to expand two to one hundred times, particularly preferably four to fifty times and very particularly preferably ten to twenty times its volume after passage through the esophagus.
  • the agent according to the invention can also be used as a carrier for a wide variety of applications.
  • it can be used as a carrier for pharmaceuticals and food supplements or foods.
  • the carriers are used for the production of orally or rectally ingestible agents, it is essential that, as with the use of saturants, it is ensured that the sponge structure is retained when compressed. The sponge structure must also be preserved when the carrier swells.
  • the agent according to the invention can i.a. pharmaceutically active substances, foods or food supplements, e.g. Contain vitamins, fiber, proteins, minerals as well as other food substances, stimulants or flavorings.
  • auxiliary substances can also be added to the sponge-like material.
  • retarding substances can also be considered if pharmaceutically active substances are used.
  • the agents according to the present invention may additionally contain fillers, disintegrants, binders and lubricants as well as carriers.
  • Active ingredients can also be introduced into the sponge-like structure.
  • Active substances in the sense of the invention are understood to mean all substances with a pharmaceutical or biological effect.
  • Examples are betamethasone, thioetic acid, sotaiol, salbutamol, norfenefrin, solymarin, dihydroergotamine, buflumedil, etofibrate, indomethacin, oxazepam, beta- acetyldigoxime, piroxicam, haioperidol, ISMN, amitirptylin, verifinipinolinodinolipinolipinolipinolipinolipinolipin, difinodinolipin, difinodinolipin, difinodinolipin, difinodinolipidolin, dopinolipin Methylprednisolone, clonidine, fenofibrate, allopurinol, pirenzepin, levothyroxine, tamoxifen, metildigoxin, o
  • Etofyllinclofibrat Vincamin, Cinarizin, Diazepam, Ketoprofen, Flupentixol, Molsidomin, Glibornuid, Dimetinden, Melperon, Soquinolol, Dibydrocodein, Clomethiazol, Clemastin, Glisoxepid, Kallidinogenase, Oxyfedrin, Baclofen, carboxymethylcysteine, thiorodacin, betathistine, L-tryptophan, myrtol, bromalaine, prenylamine, salazosulfapyridine, astemizole, sulpiride, benzerazide, dibenzepine, acetylsalicylic acid, miconazole, nystatin, ketonconulfin, colinifinocinolate, colifinocinolate, colifinocinolate, naifinocinolate, colifinocinolate, naif
  • Mucopolysaccharide polysulfuric acid ester triazolam, mianserin, tiaprofenic acid, amezinium metilsulfate, mefloquine, probucol, quinidine, carbamepine, Mg-L-aspartate, penbutolol, piretanide, amitriptyline, cyproterone, Na-valpropinate, modratinyl, mebeverinine Phenprocoumon, amantadine, naproxen, cartelol, famotidine, methyldopa, auranofin, estriol, nadolol, levomepromazine, doxorubicin, medofenoxate, azathioprine, flutamide, norfloxacin, fendiline, prajmalium bitartrate, aescin.
  • acetaminophen paracetamol
  • acetohexamide acetyldigoxime
  • acetylsalicylic acid acromycin
  • anipamil benzocaine
  • beta-carotene beta-carotene
  • choramphenicol chlordiazepoxide
  • chlormadinoacetate chlorthiazide
  • cinnarizine donazepamethonone
  • clonazepamoxinone clonazepamoxinone
  • clonazepamoxinone clonazepamoxinone
  • clonazepamoxinone digoxin
  • excipients can also be added to the carrier material.
  • additional retarding substances can also be considered.
  • Essentially water-insoluble auxiliaries or mixtures thereof, such as lipids, etc. can be used as retarding auxiliaries.
  • Fatty alcohols e.g. Cetyl alcohol, stearyl alcohol and cetostearyl alcohol
  • Glycerides e.g. Glycerol monostearate or mixtures of mono-, di- and triglycerides of vegetable oils
  • hydrogenated oils such as hydrogenated castor oil or hydrogenated cottonseed oil
  • Waxes e.g. Beeswax or camauba wax
  • solid hydrocarbons e.g. Paraffin or earth wax
  • Fatty acids e.g. stearic acid
  • certain cellulose derivatives e.g.
  • Ethyl cellulose or acetyl cellulose Ethyl cellulose or acetyl cellulose; Polymers or copolymers such as polyalkylenes, e.g. Polyethylene, polyvinyl compounds e.g. Polyvinyl chloride or polyvinyl acetate, as well as vinyl chloride-vinyl acetate copolymers and copolymers with crotonic acid, or polymers and copolymers of acrylates and methacrylates, e.g. Copolymers of acrylic acid ester and methacrylic acid methyl ester can be used.
  • polyalkylenes e.g. Polyethylene
  • polyvinyl compounds e.g. Polyvinyl chloride or polyvinyl acetate
  • vinyl chloride-vinyl acetate copolymers and copolymers with crotonic acid or polymers and copolymers of acrylates and methacrylates, e.g. Copolymers of acrylic acid ester and meth
  • the resulting material which is sparingly soluble or slightly absorbable in water and / or gastrointestinal liquids, can then be compressed. This can be done by pressing, rolling or comparable methods. Furthermore, the material can be compressed by chewing movements when the material is taken orally.
  • the material Before, during or after the production of the sponge-like structure, the material can be effective, for example, with the above-mentioned
  • Substances are applied. All the usual methods are used for this Consideration. In the simplest case, this can be done during the production phase of the sponge material by mixing the carrier material and the active substance. These substances can also be applied to the surface.
  • the sponge-like structure thus produced can be coated with the aforementioned substances. That is, either a container is made from the substance, e.g. a capsule shell, produced and the sponge-like structure introduced into this. Or the substance is applied directly to the structure, for example by dipping, spraying, spreading or similar methods. In another embodiment of the invention, the sponge-like structure is introduced into the fabric. This can e.g. can be achieved by watering.
  • the sponge or foam body made of natural, semi-synthetic or synthetic polymers, manufactured in the manner described, retains special properties Cross-linking points, in particular ionic or covalent bonds over several hours, its original form.
  • Decompression of the agent according to the invention in the stomach stimulates the stretching receptors of the stomach, which triggers a feeling of satiety and the release of any food, nutritional supplements, diet or medication that may be present.
  • the sponge according to the invention is only dissolved with difficulty in the stomach.
  • the agent according to the invention is taken orally.
  • the solid sponge or solid foam body happens by adding
  • Pharynx and esophagus preferably floats back up to its original volume in the stomach through the gastric fluid. If necessary, the volume can also be larger or smaller than the original one.
  • the oral intake of the agent according to the invention ensures that the solid sponge or solid foam body remains in the stomach for several hours due to the poor solubility in the stomach. As a result, a long-term feeling of satiety or fullness can be achieved, which results in reduced food intake.
  • the agent can also be used in the fields of pharmacy and / or health care, preferably (diet) nutrition or nutritional supplements.
  • the agent contains the active ingredients or foods already described above.
  • the duration of saturation can be controlled by the length of stay of the volume sponges.
  • the present invention relates to the use of the compositions according to the invention for the production of compositions for producing a satiety effect and for the production of medicaments which can be administered orally, anal or vaginally, foodstuffs exposed to active substances, nutritional supplements or dietetic foods.
  • the sponge-like material according to the invention can be acted upon with the separated substances in such a way that with the increase in volume it becomes retarding and long-lasting Drug release is coming.
  • Use for implants is also conceivable. These can also contain the substances mentioned.
  • the agents according to the invention can also develop their effect after they have passed through the stomach, that is to say in the intestine.
  • the agent has a stimulating effect on intestinal activity by stimulating the stretch receptors in the intestinal wall.
  • the agent can also be designed such that the decompression takes place only in the intestine.
  • the agent does not work in the stomach, but only in the intestine.
  • it is preferably provided to provide the polymers with a compound which does not dissolve in the stomach but only in the intestine, so that the compressed spongy structure can only decompress there.
  • the resolution of the connection is different, for. T. also simultaneously affects prevailing parameters in the intestine, such as. B. pH, pressure, redox potential and enzymatic dissolution by the intestinal flora.
  • the residence time of the agent in the intestine also affects the rate at which the compound dissolves.
  • the compound preferably dissolves at a pH between 5 and 10, preferably between 7 and 9, particularly preferably between 5.5 and 8.5. Dissolution in the pH environment of the intestine at a pH between 6.4 and 7.0 is most preferred. Substances which dissolve depending on the redox potential, enzymatic activities and pressure are particularly suitable.
  • the compound is preferably applied to the sponge-like structure in the form of a coating can optionally also be constructed from several layers.
  • the minimum layer thickness can vary considerably and depends on the film former used and its composition.
  • Osterwald H. et al. (Acta Pharm Technol, 1980, 26: 201-209) describes, for example, a minimum layer thickness of 46 ⁇ m for the preparation of a film former in organic solvents; with an ammonium salt solution, a layer thickness of 161 ⁇ m is required, as an emulsion after drying 46 ⁇ m and as a latex dispersion after drying 52 ⁇ m layer thickness.
  • the layer thickness is between 10 ⁇ m to several millimeters, preferably between 15 ⁇ m to 3 mm.
  • the sponge-like structure can also be introduced into a container that dissolves under the conditions described above. This means that the container is stable in the stomach while it dissolves in the intestine.
  • connection can be introduced into the sponge-like structure. This can be achieved, for example, by soaking in a solution of the compound or by admixing the compound during the production of the sponge-like structure.
  • an impregnated structure can also be provided with a coating of the connection.
  • the impregnated structure can also be introduced into the container described above.
  • the structure can be introduced into a container, which in turn is coated or impregnated with the connection or into which the connection is introduced.
  • the temporal and local resolution of the connection can be determined by the Influence the selection and combination of the compounds, whereby a targeted release of the spongy structure in the intestine and in particular in the different intestinal sections, such as jejunum, ileum and colon, is achieved.
  • the solubility of the compounds can depend on one or more factors, such as pH, exposure time, redox potential of the intestine, enzymatic activities of the intestinal flora or pressure generated by intestinal peristalsis.
  • the various options for controlling the release of active substances have been described in large numbers.
  • Hydroxypropyl methyl cellulose phthalate HPMCP 55), hydroxypropyl methyl cellulose acetate succinate (Aqoat AS-MF. Aqoat AS-HF), 1: 1 copolymer of methacrylic acid and ethyl acrylate (Eudragit ® L), copolymer of vinyl acetate and crotonic acid (coating CE 5142), cellulose acetate phthalate (CAP, Aquateric), methacrylate copolymers (Eudragit ® S), shellac, carnauba wax, hydroxypropylmethyl cellulose, polyethylene glycol, cross-linked polyethylene glycol, ethyl cellulose, ethyl cellulose-ethanol mixture, hydroxypropyl cellulose, hydroxypropylmethyl cell Monostearate, Eudragit ® E.
  • Hydrogels made from azo compounds are also possible, such as, for example, N-substituted methacrylamide, N-tert-butylacrylamide, acrylic acid in the presence of 4,4'-bis (methacryloylamino) azobenzene, 4,4 ' -Bis (N-methacryloyl-6-amino-hexanoylamino) azobenzene or 3,3 ', 5,5'-tetrabromo-4,4,4', 4'-tetra (meth-acryloylamino) azobenzene.
  • azo compounds such as, for example, N-substituted methacrylamide, N-tert-butylacrylamide, acrylic acid in the presence of 4,4'-bis (methacryloylamino) azobenzene, 4,4 ' -Bis (N-methacryloyl-6-amino-hexanoylamino) azobenzene or 3,3 ',
  • linear polymer precursors for example containing N, N-dimethylacrylamide, N-tert-butylacrylamide, acrylic acid, N-methacryloyl-glycyl-glycine-p-nitrophenyl ester, cross-linked by suitable cross-linkers, such as N, N'- (o> aminocaproyl) -4,4'-diaminoazobenzenes and polymers containing azo compounds, such as 2-hydroxyethyl methacrylate, 4- (methacryloyloxy) azobenzenes, N- (2-hydroxypropyl) methacrylamide
  • Copolymers copolymers containing styrene and 2-hydroxyethyl methacrylate crosslinked by, for example, 4,4'-divinyl azobenzene or N, N'-bis ( ⁇ -sterylsulfonyl) -4,4'-diaminoazobenzene.
  • poly (ether ester) azo polymers can be used according to the invention, such as, for example, copolymers containing 4- [4 - [(6-hydroxyhexyl) oxy] phenyl] azobenzoic acid and 16-hydroxyhexadecanoic acid, copolymers containing 4- [2- [ 2- (2-hydroxyethoxy) ethoxy] ethoxy] benzoic acid, 4- [4- [2- [2- (2-hydroxyethoxy) ethoxy] ethoxy] phenyl] azobenzoic acid and 16-hydroxyhexadecanoic acid or 12-hydroxydodecanoic acid and segmented polyurethanes containing m-xylene diisocyanate, 3,3'-dihydroxyazobenzene, polyethylene glycol or 1,2-propanediol.
  • pectins are used which can also be coated or embedded in a matrix, such as methoxy pectin, amidated pectin, calcium pectinate, pectin in combination with ethyl cellulose (Aquacoat, Surelease), acrylic acid ester polymers (Eudragit RS30D, Eudragit NE30D). Combinations of pectins with other fibers are also used. Examples of fiber are guar (galactomannan) or chitosan, where the fiber itself can in turn be coated or be part of a matrix.
  • film formers polymethacrylate solutions, copolymers containing polyurethane and di-, oligo- or polysaccharides (galactomannans) and ethylgalactomannans or acetylgalactomannans.
  • cyanoacrylate, inulin, inulin suspensions with Eudragit-RS, methacrylated inulin, chondroitin sulfate, containing chondroitin polymers containing 12-diaminododecane and dicyclohexylcarbodiimide, amorphous amylose or amorphous amylose are used together with other film-forming polymers as film formers.
  • Dextrans can also be used, which can be crosslinked in various ways, for example with diisocyanates, fatty acid esters, for example lauric acid, glutaraldehyde. Conjugates of biphenylacetic acid and ⁇ -cyclodextrin, films of ⁇ -cyclodextrins with methacrylic acid copolymers or acrylic acid polymers with disaccharide side groups are also used according to the invention.
  • the sponge-like material produced by the method according to the invention is also suitable for external use in humans and animals. For example, it can be used as a wound dressing to treat wounds. Use as a carrier material for dermatological applications is also conceivable. The material is also suitable for cosmetic applications, e.g. B. face masks or skin care pads. It is also suitable for implants.
  • the sponge-like material can be treated with suitable substances. I.e. it can contain therapeutic, cosmetic and other active ingredients as well as customary auxiliaries.
  • a 4% aqueous sodium alginate solution is prepared.
  • the gel structure is solidified by salt formation.
  • the solution is placed in dishes and frozen at minus 20 degrees for 12 to 24 hours into plates with a thickness of 4 to 5 cm.
  • the frozen plates are removed from the trays and placed in an insulated container at temperatures from minus 10 to 0 degrees Celsius soaked in isopropyl alcohol or ethanol for 24 hours.
  • the isopropyl alcohol is removed by dripping, centrifuging or squeezing.
  • the gel structure insoluble in isopropyl alcohol remains.
  • the resulting alginate plate is then dried at 50 degrees Celsius.
  • the dried plates are then cut compressed and inserted into capsules. These capsules can then be sold directly as saturation agents.
  • a 10% collagen solution is frozen in the form of a plate.
  • the frozen plate is placed in isopropanol for 24 hours.
  • the sponge is heated to 95 ° C in a pressure vessel to denature and solidify the collagen. Then drying takes place.
  • Alginate with wheat fibers Alginate with wheat fibers:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de production de matières spongieuses, selon lequel une solution contenant des polymères est produite ; le liquide est éliminé par l'ajout de substances appropriées puis la solution est séchée. Ladite invention concerne également une matière spongieuse produite selon ce procédé ainsi que son utilisation en tant qu'excipients pour principes actifs dans et sur le corps ou produits alimentaires ainsi que dans la production de médicaments, de produits cosmétiques, de produits alimentaires et d'agents saturants ainsi que de pansements et en tant qu'implant pouvant contenir des principes actifs.
EP03813570A 2002-12-19 2003-12-16 Procede de production de matieres spongieuses Withdrawn EP1572256A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE2002159505 DE10259505A1 (de) 2002-12-19 2002-12-19 Verfahren zur Herstellung von schwammartigen Materialien
DE20219660U 2002-12-19
DE10259505 2002-12-19
DE20219660U DE20219660U1 (de) 2002-12-19 2002-12-19 Schwammartiges Material
PCT/EP2003/014294 WO2004056908A2 (fr) 2002-12-19 2003-12-16 Procede de production de matieres spongieuses

Publications (1)

Publication Number Publication Date
EP1572256A2 true EP1572256A2 (fr) 2005-09-14

Family

ID=32683454

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03813570A Withdrawn EP1572256A2 (fr) 2002-12-19 2003-12-16 Procede de production de matieres spongieuses

Country Status (3)

Country Link
EP (1) EP1572256A2 (fr)
AU (1) AU2003300525A1 (fr)
WO (1) WO2004056908A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3143114B1 (fr) 2014-07-11 2023-12-13 The Procter & Gamble Company Particules structurées comprenant un copolymère greffé amphiphile, et détergent granulaire pour la lessive comprenant ces particules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0838491A2 (fr) * 1996-10-28 1998-04-29 Johnson & Johnson Medical Ltd. Eponges de polysaccharide séchée au moyen d'un solvant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619250A (en) * 1968-07-18 1971-11-09 Kanegafuchi Spinning Co Ltd Method for making microporous sheet material
DE19623703C1 (de) * 1996-06-14 1997-07-24 Freudenberg Carl Fa Schwamm und Verfahren zu dessen Herstellung
DE19942417A1 (de) * 1999-09-06 2001-03-08 Guenther Beisel Vernetztes Mittel zur Erzeugung eines langanhaltenden Sättigungseffekts und Verfahren zu dessen Herstellung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0838491A2 (fr) * 1996-10-28 1998-04-29 Johnson & Johnson Medical Ltd. Eponges de polysaccharide séchée au moyen d'un solvant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004056908A3 *

Also Published As

Publication number Publication date
AU2003300525A8 (en) 2004-07-14
WO2004056908A2 (fr) 2004-07-08
WO2004056908A3 (fr) 2004-11-11
AU2003300525A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
US6677318B1 (en) Cross-linked agent for generation of a long-lasting satiety effect and method for the production of the said
DE60026357T2 (de) An- und abschwellende polymermischungen
WO2003086360A1 (fr) Agent destine a generer une sensation de satiete et une reduction ponderale
EP1209988B1 (fr) Substance reticulee servant a produire un effet rassasiant durable et procede de production correspondant
Lalarukh et al. Microencapsulation: an innovative technology in modern science
DE19942417A1 (de) Vernetztes Mittel zur Erzeugung eines langanhaltenden Sättigungseffekts und Verfahren zu dessen Herstellung
EP0948316B1 (fr) Agent pour produire un effet de saturation de longue duree
EP0936903B1 (fr) Produit a effet retard
EP1572256A2 (fr) Procede de production de matieres spongieuses
DE20219660U1 (de) Schwammartiges Material
DE29915656U1 (de) Vernetztes Mittel zur Erzeugung eines langanhaltenden Sättigungseffekts
DE10259505A1 (de) Verfahren zur Herstellung von schwammartigen Materialien
EP1210071A1 (fr) Moyen pour ameliorer et maintenir l'activite intestinale, et son procede de production
DE29915668U1 (de) Mittel zur Verbesserung und Erhaltung der Darmtätigkeit
DE29915634U1 (de) Mittel zur Stimulanz der Darmtätigkeit
DE19942424A1 (de) Mittel zur Verbesserung und Erhaltung der Darmtätigkeit sowie Verfahren zu dessen Herstellung
DE19942365A1 (de) Mittel zur Stimulanz der Darmtätigkeit sowie Verfahren zu dessen Herstellung
EP1210070A1 (fr) Substance destinee a stimuler l'activite intestinale et procede de preparation de ladite substance
Ribeiro Emerging technologies of hydrogels in bioactive compounds delivery
DE10247910A1 (de) Mittel zur Erzeugung eines langanhaltenden Sättigungseffektes
DE10259508A1 (de) Mittel zur Erzeugung eines Sättigungseffekts und zur Gewichtsreduzierung
DE10259504A1 (de) Verfahren zur Herstellung eines oral einnehmbaren Mittels enthaltend schwammartige Materialien
DE10259507A1 (de) Mittel zur Erzeugung eines Sättigungseffekts und zur Gewichtsreduzierung bei Tieren
DE20219662U1 (de) Oral einnehmbares Mittel enthaltend schwammartige Materialien
WO2004056209A1 (fr) Agent contenant du ginseng destine a la creation d'un effet de satiete et a la reduction de poids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050608

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070125

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070807